Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
VYD222
DRUG
2 trials
Sponsors
Invivyd, Inc.
Conditions
COVID-19
Phase 1
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants
Completed
NCT05791318
Invivyd, Inc.
COVID-19
Start: 2023-03-28
End: 2024-05-08
Updated: 2024-05-31
Unknown Phase
Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
NCT06004128
Invivyd, Inc.
COVID-19
Updated: 2024-06-03
Related Papers
1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention
Open Forum Infectious Diseases
2023-11-27
2 citations
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
Open Forum Infectious Diseases
2023-06-13
20 citations
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate COVID-19: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Open Forum Infectious Diseases
2023-05-24
12 citations